– As part of an ongoing global vision in Reimagining Medicine for patients, healthcare providers and healthcare systems – leading multinational biopharmaceutical company Novartis Malaysia kept nearly 210,300 frontline healthcare workers and at-risk communities nationwide safe from Covid-19 with a contribution of RM2.7 million for PPE items, hand sanitizers, Covid-19 testkits and hardware support for vaccination centers.
When Covid-19 spiraled into a global health crisis in 2020, Novartis Malaysia as the leading multinational biopharmaceutical committed to the urgent need to keeping healthcare front-liners and at-risk communities nationwide safe. With a total contribution of RM2.7mil across 2020 and 2021, the company has provided PPEs, hand sanitizers and rapid test kits as the immediate response and recovery efforts related to the pandemic outbreak in Malaysia.
Beyond the pandemic, on an Environmental, Social and Governance front, globally Novartis continues to advance its agenda in issuing a bond linked to targets for global health and access to medicine i.e., increasing access to our strategic innovative therapies by 200% in low and middle-income countries by 2025. To support the increasing number of Malaysian Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumor (GIST) patients for treatment, our Novartis Oncology Access helped provide universal coverage for nearly a decade under the Malaysian Patient Assistance Program (MYPAP), a cost-sharing contribution model in partnership with the Ministry of Health (MoH). This unique model enables the annual treatment cost to be partially covered by both MoH and Novartis. To date, it has supported over 2,000 people living with CML and GIST.
The company has also committed to the preservation of the environment by setting new targets to be carbonneutral across our value chain by 2030. In Malaysia, we have successfully implemented a 100% elimination of Single Use Plastics to meet our plastic neutrality goals.